top of page

Gastrointestinal System

Primary biliary cholangitis, primary sclerosing cholangitis

Core Principle of Cholestatic Liver Disease
🧷 Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic diseases that progressively destroy bile ducts, leading to cholestasis → fibrosis → cirrhosis.
🧷 PBC targets small intrahepatic bile ducts via autoimmune destruction, while PSC affects both intrahepatic and extrahepatic ducts via inflammation and fibrosis.
🧷 Both present with cholestatic biochemical pattern: ↑alkaline phosphatase (ALP) and ↑GGT out of proportion to transaminase elevation.
🧷 Understanding the pathophysiology, demographics, autoantibody profiles, and associations drives board-level differentiation.
Solid White Background
Primary Biliary Cholangitis: Autoimmune Destruction
📍 PBC is an autoimmune disease causing granulomatous destruction of small intrahepatic bile ducts, predominantly affecting middle-aged women (F:M ratio 9:1).
📍 Pathogenesis: autoreactive T cells target biliary epithelial cells → chronic inflammation → ductopenia (loss of bile ducts) → cholestasis.
📍 Classic histology shows lymphocytic portal inflammation with granulomatous destruction of bile ducts — the "florid duct lesion."
📍 Progressive ductopenia leads to periportal fibrosis → bridging fibrosis → cirrhosis over 10-20 years if untreated.
Solid White Background
PBC Clinical Presentation and Natural History
🔹 Early disease is often asymptomatic, discovered incidentally via elevated ALP on routine labs.
🔹 Fatigue and pruritus are the most common initial symptoms — pruritus classically worse at night, on palms/soles.
🔹 As cholestasis progresses: jaundice, xanthomas (cholesterol deposits), fat-soluble vitamin deficiencies (A, D, E, K).
🔹 Associated autoimmune conditions: Sjögren syndrome (up to 50%), autoimmune thyroiditis, CREST syndrome.
🔹 Board pearl: Middle-aged woman with fatigue, pruritus, and elevated ALP → think PBC and check anti-mitochondrial antibodies.
Solid White Background
Anti-Mitochondrial Antibodies: The PBC Hallmark
⭐ Anti-mitochondrial antibodies (AMA) are present in 95% of PBC patients — highly sensitive and specific.
⭐ AMA target the E2 subunit of pyruvate dehydrogenase complex on the inner mitochondrial membrane.
⭐ AMA-positive with cholestatic LFTs is virtually diagnostic of PBC; liver biopsy rarely needed for diagnosis.
⭐ The 5% who are AMA-negative often have anti-nuclear antibodies (anti-GP210 or anti-SP100) — "AMA-negative PBC."
⭐ Board distinction: AMA is to PBC what anti-smooth muscle antibodies are to autoimmune hepatitis.
Solid White Background
Primary Sclerosing Cholangitis: Fibroinflammatory Obliteration
✅ PSC causes progressive fibrosis and obliteration of both intrahepatic and extrahepatic bile ducts, creating a "beaded" appearance on imaging.
✅ Affects young to middle-aged men (M:F ratio 2:1), with 70-80% having concurrent inflammatory bowel disease (usually ulcerative colitis).
✅ Pathogenesis unclear: likely involves genetic susceptibility, altered gut microbiome, and immune dysregulation.
✅ No diagnostic autoantibodies — diagnosis requires imaging showing multifocal biliary strictures and dilatations.
Solid White Background
PSC Clinical Features and Associations
🧠 Often asymptomatic early, presenting with elevated ALP found during IBD workup.
🧠 Progressive symptoms: fatigue, pruritus, jaundice, right upper quadrant pain, recurrent bacterial cholangitis.
🧠 Strong association with ulcerative colitis (70-80%) > Crohn disease; IBD may precede, coincide with, or follow PSC diagnosis.
🧠 Increased risk of cholangiocarcinoma (10-15% lifetime risk) and colorectal cancer (especially with concurrent UC).
🧠 Board pearl: Young man with UC and elevated ALP → obtain MRCP to evaluate for PSC.
Solid White Background
Imaging in PSC: The Beaded Bile Duct
⚡ MRCP (magnetic resonance cholangiopancreatography) is the diagnostic imaging of choice — non-invasive visualization of biliary tree.
⚡ Classic finding: multifocal strictures alternating with normal or dilated segments → "beads on a string" appearance.
⚡ Affects both intrahepatic and extrahepatic ducts; isolated small-duct PSC exists but is rare.
⚡ ERCP reserved for therapeutic intervention (stricture dilation, stenting) due to risk of pancreatitis and cholangitis.
⚡ Board clue: "Beaded" or "pruned tree" appearance of bile ducts = PSC.
Solid White Background
Laboratory Patterns: Cholestasis in Both Diseases
📌 Both PBC and PSC show cholestatic pattern: ↑ALP and ↑GGT >> ↑AST/ALT.
📌 Bilirubin elevation indicates advanced disease in both conditions.
📌 Hypercholesterolemia common, especially in PBC (predominantly HDL early, then LDL as disease progresses).
📌 IgM often elevated in PBC; IgG4 may be elevated in a subset of PSC (IgG4-associated sclerosing cholangitis).
📌 Board distinction: Isolated ALP elevation in middle-aged woman → check AMA for PBC; in young man with IBD → image for PSC.
Solid White Background
Complications of Chronic Cholestasis
📣 Fat-soluble vitamin deficiencies (A, D, E, K): night blindness, osteoporosis, neuropathy, coagulopathy.
📣 Metabolic bone disease: osteoporosis >> osteomalacia due to vitamin D deficiency and calcium malabsorption.
📣 Pruritus: from bile salt deposition in skin; can be severe and debilitating.
📣 Xanthomas and xanthelasmas: cholesterol deposits from hyperlipidemia.
📣 Portal hypertension complications develop with progression to cirrhosis in both diseases.
Solid White Background
PBC Treatment: UDCA as First Line
🔸 Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day is first-line therapy — improves liver biochemistry and delays disease progression.
🔸 UDCA works by promoting bicarbonate-rich choleresis, reducing hydrophobic bile acid toxicity, and having anti-inflammatory effects.
🔸 Response defined as ALP <1.5× upper limit of normal after 1 year — predicts improved transplant-free survival.
🔸 Second-line for inadequate responders: obeticholic acid (FXR agonist) — but contraindicated in decompensated cirrhosis.
🔸 Liver transplantation for end-stage disease; PBC has excellent post-transplant outcomes.
Solid White Background
PSC Management: No Proven Medical Therapy
🧷 Unlike PBC, no medical therapy has proven efficacy in slowing PSC progression — UDCA trials showed no survival benefit.
🧷 Management focuses on complications: fat-soluble vitamins, treating pruritus, managing portal hypertension.
🧷 Dominant strictures may benefit from endoscopic dilation ± stenting to relieve obstruction.
🧷 Surveillance for cholangiocarcinoma with CA 19-9 and MRI/MRCP every 6-12 months.
🧷 Liver transplantation is definitive therapy; PSC recurs in ~25% of transplants.
Solid White Background
Overlap Syndromes and Variants
📍 PBC-autoimmune hepatitis overlap: features of both diseases; requires immunosuppression plus UDCA.
📍 Small-duct PSC: normal cholangiography but liver biopsy shows characteristic changes; better prognosis than classic PSC.
📍 IgG4-associated sclerosing cholangitis: mimics PSC but responds to steroids; elevated serum IgG4, infiltration on histology.
📍 PSC-autoimmune hepatitis overlap: especially in children/young adults; worse prognosis than either disease alone.
📍 Board pearl: Overlaps require features of both diseases, not just abnormal labs.
Solid White Background
Malignancy Risk: Different Patterns
🔹 PSC has high cholangiocarcinoma risk (10-15% lifetime) — can occur at any stage, even pre-cirrhotic.
🔹 PSC with UC has increased colorectal cancer risk beyond UC alone → annual colonoscopy from diagnosis.
🔹 PBC has increased hepatocellular carcinoma risk only after developing cirrhosis (similar to other causes of cirrhosis).
🔹 Gallbladder polyps in PSC often malignant → cholecystectomy for any polyp regardless of size.
🔹 Board distinction: PSC → cholangiocarcinoma risk; PBC → HCC only with cirrhosis.
Solid White Background
Pruritus Management in Cholestasis
⭐ First-line: bile acid sequestrants (cholestyramine) — bind bile acids in gut, reducing enterohepatic circulation.
⭐ Timing crucial: give cholestyramine 4 hours apart from other medications (especially UDCA) to avoid binding.
⭐ Second-line options: rifampin (enzyme inducer), naltrexone (opioid antagonist), sertraline (SSRI).
⭐ Severe refractory pruritus may require plasmapheresis or molecular adsorbent recirculating system (MARS).
⭐ Board pearl: Cholestyramine can worsen fat-soluble vitamin deficiency — monitor and supplement.
Solid White Background
Histologic Patterns and Staging
✅ PBC stages: Stage 1 (portal inflammation) → Stage 2 (periportal fibrosis) → Stage 3 (bridging fibrosis) → Stage 4 (cirrhosis).
✅ PBC hallmark: "florid duct lesion" — granulomatous destruction of bile ducts with epithelioid cells.
✅ PSC shows "onion-skin fibrosis" — concentric periductal fibrosis creating characteristic layered appearance.
✅ Both show progressive ductopenia (loss of bile ducts) with disease progression.
✅ Board clue: Granulomas around bile ducts = PBC; onion-skin fibrosis = PSC.
Solid White Background
Diagnostic Approach to Cholestatic LFTs
🧠 Step 1: Confirm cholestatic pattern (↑ALP, ↑GGT) and rule out obstruction with imaging (ultrasound or MRCP).
🧠 Step 2: Check AMA for PBC — if positive with appropriate clinical context, diagnosis confirmed.
🧠 Step 3: If AMA negative, obtain MRCP to evaluate for PSC (beading, strictures).
🧠 Step 4: Consider liver biopsy if imaging normal but high suspicion for small-duct PSC or AMA-negative PBC.
🧠 Additional tests: ANA, anti-smooth muscle antibodies (for overlap syndromes), IgG4 (for IgG4-related disease).
Solid White Background
Pregnancy Considerations
⚡ PBC generally improves during pregnancy (immunotolerance effect) but may flare postpartum.
⚡ UDCA is safe in pregnancy (FDA category B) and should be continued.
⚡ PSC has variable course in pregnancy; increased risk of preterm delivery and fetal complications.
⚡ Both diseases increase risk of intrahepatic cholestasis of pregnancy (ICP) — monitor bile acids.
⚡ Board pearl: Worsening pruritus in third trimester with cholestatic disease → check bile acids for ICP.
Solid White Background
Liver Transplantation Outcomes
📌 PBC has excellent post-transplant survival (>90% at 5 years); disease recurs in 20-30% but rarely affects graft survival.
📌 PSC has good outcomes but higher recurrence rate (~25%) which can affect graft survival.
📌 Living donor transplant outcomes similar to deceased donor for both diseases.
📌 Post-transplant screening: PBC recurrence suggested by rising ALP and AMA; PSC recurrence requires imaging.
📌 Retransplantation may be needed for recurrent disease, especially PSC.
Solid White Background
Board Question Stem Patterns
📣 Middle-aged woman + fatigue + pruritus + ↑ALP + positive AMA → PBC.
📣 Young man + IBD + ↑ALP + beaded bile ducts on MRCP → PSC.
📣 Cholestatic LFTs + granulomas around bile ducts → PBC.
📣 Cholestatic LFTs + onion-skin periductal fibrosis → PSC.
📣 PSC patient + new jaundice + weight loss + CA 19-9 elevation → cholangiocarcinoma.
📣 PBC patient + inadequate response to UDCA → add obeticholic acid.
📣 Severe pruritus + cholestyramine timing → separate from other meds by 4 hours.
Solid White Background
One-Line Recap
🔸 PBC (AMA-positive, middle-aged women, small duct destruction) and PSC (beaded ducts on imaging, young men with IBD, cholangiocarcinoma risk) are progressive cholestatic diseases differentiated by antibodies, imaging patterns, demographics, and treatment response to UDCA.
Solid White Background
bottom of page